CommercialCoverageHigh impact
Nonstandard Laboratory Test Panels (CPB 0499, reviewed 2026-08-03)
Aetna·Medical Policy
Effective date
Aug 3, 2026
We identified it
Aug 19, 2026
Summary
Aetna has updated its policy on nonstandard laboratory test panels (CPB 0499) to designate specific panels from multiple specialty laboratories as experimental, investigational, or unproven. This policy denies coverage for these nonstandard panels unless there is documented medical necessity with specific signs and symptoms. Billing teams must identify when these panels are ordered and deny claims or require prior authorization before services are rendered.
Action Required
By August 3, 2026: Billing team must implement the following: (1) Update billing system to flag and deny claims for all nonstandard laboratory test panels listed in CPB 0499 from the following laboratories: Aeron Life Cycles, Alletess Medical Laboratory, BioHealth, DiagnosTechs, Doctor's Data Lab, Great Plains Laboratory, Moleculera Labs, Physicians Lab, ZRT Laboratory, and 20+ other specialty labs listed in the policy. (2) Create a blocklist in the electronic health record (EHR) and billing software that prevents billing of these specific panels without prior authorization documentation. (3) Front office staff must inform patients that these tests require pre-authorization and documented medical necessity (specific signs and symptoms) before ordering. (4) Providers must document specific clinical indicators on all requisition forms for tests listed as experimental. (5) Billing staff should establish a prior authorization workflow for any claims that slip through, noting exceptions where limited medical necessity exists (e.g., amino acid testing for neonates, urine fluoride for toxicity symptoms). Failure to implement these controls will result in automatic claim denials by Aetna for all nonstandard panels without proper prior authorization and medical necessity documentation.